captopril has been researched along with spiraprilat in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Baum, T; Gold, EH; McNamara, P; Neustadt, BR; Smith, EM; Swiss, GF; Sybertz, EJ | 1 |
| Cushman, DW; DeForrest, JM; Duggan, M; Karanewsky, DS; Krapcho, J; Powell, JR; Rovnyak, G; Schwartz, J; Spitzmiller, ER; Turk, C | 1 |
| Barnett, A; Baum, T; Pula, K; Tedesco, RP; Watkins, RW | 1 |
3 other study(ies) available for captopril and spiraprilat
| Article | Year |
|---|---|
Angiotensin converting enzyme inhibitors: spirapril and related compounds.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pressure; Chemical Phenomena; Chemistry; Dogs; Enalapril; Male; Phenylbutyrates; Rats; Rats, Inbred Strains; Spiro Compounds | 1989 |
Angiotensin-converting enzyme inhibitors. Mercaptan, carboxyalkyl dipeptide, and phosphinic acid inhibitors incorporating 4-substituted prolines.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pressure; Captopril; Enalapril; Enalaprilat; Kinetics; Male; Phosphinic Acids; Rats; Rats, Inbred Strains; Structure-Activity Relationship | 1988 |
Systemic effects resulting from topical ocular administration of SCH 33861, a novel ACE inhibitor ocular hypotensive agent.
Topics: Administration, Topical; Angiotensin I; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pressure; Captopril; Heart Rate; Intraocular Pressure; Male; Phenylbutyrates; Rabbits; Spiro Compounds | 1988 |